الفهرس 
Estimation of Interleukin-29 level in psoriasis before and after narrow-band ultraviolet Is metabolic syndrome a hidden culprit?
AbstractOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Background: Although it is now considered a prototypic T helper 1/ T helper 17-mediated disease, several gaps still exist in our understanding of the pathogenesis of psoriasis. Interleukin-29 is the latest cytokine of the Interleukin -10 family. Research on interleukin-29 uncovered its pleiotropic role in the differentiation and function of distinct T-cell subsets.Objective: Our aim was to study the levels of interleukin-29 in patients with psoriasis before and after treatment by narrowband-ultraviolet B, and to assess its relation to clinical disease parameters and metabolic syndrome.Methods: Thirty psoriatic patients and 30 age, sex and skin type matched controls were included. Full clinical examination was done and both tissue and serum levels of interleukin-29 were measured by enzyme-linked immunosorbent assay before and after narrowband-ultraviolet B sessions. Biochemical labs were requested to assess the participants for metabolic syndrome.Results: The mean interleukin-29 levels in both tissue and serum of psoriasis patients were significantly higher when compared to controls (P=0.044, P=0.013 respectively).Tissue and serum levels of interleukin-29 decreased after narrowband-ultraviolet B sessions (P= 0.008 and 0.004 respectively). Patients with metabolic syndrome and high triglycerides levels showed significantly lower changes in tissue and serum interleukin-29 levels respectively (P=0.01)